Pacira BioSciences Target of Unusually High Options Trading (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) was the target of unusually large options trading on Tuesday. Stock traders bought 5,734 put options on the stock. This represents an increase of 1,898% compared to the average daily volume of 287 put options.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PCRX shares. Barclays cut Pacira BioSciences from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $38.00 to $25.00 in a research report on Wednesday. Piper Sandler reissued an “overweight” rating and set a $42.00 price target on shares of Pacira BioSciences in a report on Wednesday. JPMorgan Chase & Co. began coverage on Pacira BioSciences in a report on Thursday, March 7th. They set an “overweight” rating and a $45.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Pacira BioSciences in a report on Tuesday. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.10.

Insider Transactions at Pacira BioSciences

In other news, insider Jonathan Slonin sold 2,836 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the sale, the insider now directly owns 95,557 shares in the company, valued at $2,699,485.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Pacira BioSciences news, insider Jonathan Slonin sold 2,836 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the sale, the insider now directly owns 95,557 shares in the company, valued at $2,699,485.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Lauren Riker sold 3,970 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total value of $114,018.40. Following the completion of the sale, the senior vice president now owns 38,075 shares in the company, valued at $1,093,514. The disclosure for this sale can be found here. Insiders sold a total of 21,150 shares of company stock worth $602,170 over the last ninety days. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Pacira BioSciences by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock valued at $149,413,000 after acquiring an additional 14,960 shares during the last quarter. Frontier Capital Management Co. LLC raised its holdings in Pacira BioSciences by 15.8% in the 4th quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company’s stock valued at $70,332,000 after acquiring an additional 285,045 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Pacira BioSciences by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company’s stock valued at $47,633,000 after acquiring an additional 17,949 shares during the last quarter. Vestal Point Capital LP purchased a new stake in shares of Pacira BioSciences during the 4th quarter valued at $40,488,000. Finally, Clearbridge Investments LLC grew its stake in shares of Pacira BioSciences by 2.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company’s stock valued at $34,250,000 after buying an additional 26,463 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Trading Down 4.7 %

Shares of Pacira BioSciences stock opened at $21.66 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.81 and a quick ratio of 4.78. Pacira BioSciences has a 1 year low of $20.52 and a 1 year high of $40.16. The company has a market capitalization of $1.01 billion, a P/E ratio of 15.15 and a beta of 0.88. The business has a 50 day moving average price of $28.60 and a 200 day moving average price of $29.73.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pacira BioSciences had a return on equity of 12.98% and a net margin of 10.34%. The company had revenue of $167.12 million for the quarter, compared to analyst estimates of $165.43 million. Sell-side analysts anticipate that Pacira BioSciences will post 2.13 EPS for the current fiscal year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.